Lars Gullestad|John Kjekshus - JoVE Visualize

Showing results (1-10 of 419) with videos related to

Pageof 42

Sort By:

American Heart Journal|December 24, 2003

Predictors of exercise capacity and the impact of angiographic coronary artery disease in heart transplant recipientsLars Gullestad, Jonathan Myers, Thor Edvardsen, et al.

Expert Opinion on Investigational Drugs|June 2, 2005

Agents targeting inflammation in heart failureLars Gullestad, John Kjekshus, Jan Kristian Damås, et al.

Circulation|March 13, 2002

Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)Stephen S Gottlieb, Michael L Fisher, John Kjekshus, et al.

Journal of the American College of Cardiology|December 6, 2005

Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patientsThor Ueland, John Kjekshus, Stig S Frøland, et al.

European Heart Journal|February 18, 2005

Soluble CD40 ligand in acute and chronic heart failureThor Ueland, Pål Aukrust, Arne Yndestad, et al.

Journal of Cardiac Failure|December 3, 2014

Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trialThor Ueland, Pål Aukrust, Ståle H Nymo, et al.

American Heart Journal|December 1, 2012

The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)Lars Gullestad, Thor Ueland, John Kjekshus, et al.

Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|June 22, 2016

Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)Fizza Arain, Lars Gullestad, Ståle Nymo, et al.

Circulation. Heart Failure|November 29, 2013

Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trialJørgen Gravning, Erik T Askevold, Ståle H Nymo, et al.

Journal of the American College of Cardiology|January 18, 2005

What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)Lars Gullestad, John Wikstrand, Prakash Deedwania, et al.

Pageof 42

Showing results (1-10 of 419) with videos related to

Sort By:

Pageof 42

American Heart Journal|December 24, 2003

Predictors of exercise capacity and the impact of angiographic coronary artery disease in heart transplant recipientsLars Gullestad, Jonathan Myers, Thor Edvardsen, et al.

Expert Opinion on Investigational Drugs|June 2, 2005

Agents targeting inflammation in heart failureLars Gullestad, John Kjekshus, Jan Kristian Damås, et al.

Circulation|March 13, 2002

Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)Stephen S Gottlieb, Michael L Fisher, John Kjekshus, et al.

Journal of the American College of Cardiology|December 6, 2005

Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patientsThor Ueland, John Kjekshus, Stig S Frøland, et al.

European Heart Journal|February 18, 2005

Soluble CD40 ligand in acute and chronic heart failureThor Ueland, Pål Aukrust, Arne Yndestad, et al.

Journal of Cardiac Failure|December 3, 2014

Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trialThor Ueland, Pål Aukrust, Ståle H Nymo, et al.

American Heart Journal|December 1, 2012

The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)Lars Gullestad, Thor Ueland, John Kjekshus, et al.

Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|June 22, 2016

Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)Fizza Arain, Lars Gullestad, Ståle Nymo, et al.

Circulation. Heart Failure|November 29, 2013

Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trialJørgen Gravning, Erik T Askevold, Ståle H Nymo, et al.

Journal of the American College of Cardiology|January 18, 2005

What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)Lars Gullestad, John Wikstrand, Prakash Deedwania, et al.

Pageof 42